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The study of rare genetic diseases is complicated by the inaccessibility of relevant cells and tissues,
especially for neurologic disorders. In this issue ofCell Stem Cell, Marteyn et al. (2011) use human embryonic
stem cells to identify deficits in neuritic outgrowth in myotonic dystrophy type 1.Myotonic dystrophy type 1 (DM1) is the
most common inherited neuromuscular
disorder in adults (Llamusi and Artero,
2008). It is also one of the most variable
clinical disorders, where within one family,
the most severe form—congenital DM1
(CDM1)—can affect children at birth,
and the mildest form can result in only
cataracts in elderly individuals. Common
features of adult-onset DM1 include
myotonia (prolongedmusclecontractions),
progressive muscle wasting, cardiac con-
duction abnormalities, cataracts, hyper-
somnolence, and various personality and
executive function changes. CDM1 shows
a different spectrum of symptoms, in-
cluding hypotonia, mental retardation,
and impaired muscle development (Meola
and Sansone, 2007). DM1 is an autosomal
dominant disorder caused by an expan-
sion of a (CTG)n triplet repeat in the
30-untranslated region of the DM protein
kinase (DMPK) gene. These repeats are
expanded from a normal range (n = 5 to
z30) to greater than several thousand
repeats (n = 50 to > 2000) in affected fami-
lies. The size of the (CTG) expansion
correlates with disease severity and tends
to increase from generation to generation,
explaining the variable phenotypes within
one kindred. Accumulating data have
established DM1 as the first example of
a disorder causedbyRNA toxicity (Llamusi
and Artero, 2008). Mutant DMPK mRNA
(‘‘toxic RNA’’) aggregates into nuclear
inclusions (RNA foci) and is thought to
trigger dominant effects by interacting
with (and altering the function of) RNA-
binding proteins—primarily members of
themuscleblind (MBNL) andCELF families
of RNA-binding proteins—resulting in
aberrant splicing of various relevant
mRNAs in affected tissues.Though neurologic manifestations are
often the most pressing concern of indi-
viduals affected by DM1, little headway
has been made in understanding their
molecular basis. Using human embryonic
stem cells (hESCs) derived from embryos
with the DM1 mutation, Marteyn et al.
(2011) found that after differentiation into
neural precursor cells, SLITRK4 expres-
sion was decreased, based on global
expression analyses. Furthermore, the
authors confirmed that expression of
both SLITRK2 and SLITRK4 were
decreased in DM1 patients, after perform-
ing RT-PCR with brain tissue samples.
SLITRK4 belongs to a newly identified
family of six transmembrane proteins that
exhibit homology to the Slit family of
axonal growth factors and to trk neurotro-
phin receptors (Aruga and Mikoshiba,
2003). The SLITRKproteins are expressed
primarily in neural tissues and have been
implicated in affecting neurite outgrowth.
Marteyn et al. (2011) differentiated the
mutant hESCs into motor neurons
using a coculture system with primary
myoblasts and found that the resulting
DM1 cells had defects characterized by
increased neuritic outgrowth. Unexpect-
edly, this growth pattern was also associ-
ated with decreased synaptogenesis
(impaired neuromuscular junction [NMJ]
formation). Overexpression of SLITRK2
and SLITRK4 in DM1 hESCs rescued the
neuritic overgrowth phenotype.
How the DM1 mutation causes these
effects on SLITRK2 and SLITRK4 is
unclear. Most pathogenesis models for
DM1have focusedonRNA toxicity leading
to aberrant RNA splicing (Llamusi and
Artero, 2008). Alternative splicing of
SLITRK2 and SLITRK4 has not been well
studied, but the reported variants in theCell Stem Cpublic databases all seem to be based
onalternative50UTRsequences.Recently,
additional effects of RNA toxicity have
been reported, such as the transcriptional
effects seen with NKX2–5 (Yadava et al.,
2008). SLITRK members may be similarly
affected. Post-transcriptional effects may
also be possible since CUGBP1 has
been shown to play a role in RNA stability
(Lee et al., 2010).
The motor neuron cell culture model
employed by Marteyn et al. (2011)
suggests that there are defects in motor
neuron function and NMJ formation. It
should be noted that the coculture
experiments were done using non-DM1
myoblasts. However, in the disease state,
obviously both the motor neurons and the
myoblasts are affected, so it would be
interesting to coculture normal and DM1
hESCs with DM1 myoblasts to study the
contribution of the affected myoblasts to
the observed phenotypes. This approach
might also open new avenues for investi-
gation, as muscle is a much more acces-
sible and well-studied tissue in DM1
pathogenesis models.
In this study, the data supporting
effects on SLITRK members in patient
tissues are sparse and testify to the diffi-
culties of studying neurologic phenotypes
in rare disorders. Nevertheless, the results
are intriguing in the context of DM1, where
isolated studies dating back several
decades have reported defects in neuro-
muscular junctions and hyperproliferation
of noncholinergic synapses (Stranock and
Davis, 1978). A recent report also identi-
fied defects in NMJs in a mouse model
of DM1 expressing the toxic RNA (Panaite
et al., 2008). Also, RNA foci in subsynaptic
nuclei at the NMJs in muscle and in motor
neurons have been found in tissues fromell 8, April 8, 2011 ª2011 Elsevier Inc. 349
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Previewsindividuals with DM1, indicating that the
toxic RNA is expressed in the relevant
cells (Wheeler et al., 2007).
In childhood/juvenile-onset DM1, the
major neurologic phenotypes are often
related to behavioral changes, such as
anxiety, attention deficit hyperactivity
disorder, autistic behavior, and obses-
sive-compulsive behavior (Meola and
Sansone, 2007). In CDM1, mental retar-
dation is frequently observed in conjunc-
tion with the aforementioned behavioral
phenotypes. In adult DM1, similar behav-
ioral changes have been observed in
many patients, including anxiety, ob-
sessive-compulsive behavior, attention
deficit disorder, and apathy. In this
regard, it is of particular interest that in
recent studies using knockout mice defi-
cient for various Slitrk family members,
a variety of behavioral phenotypes
(anxiety, obsessive-compulsive behavior)
and disorganized/reduced innervations350 Cell Stem Cell 8, April 8, 2011 ª2011 Elshave been noted (reviewed in Proenca
et al., 2011). While it may be premature
and speculative, the results from these
knockout mice and the decreased levels
of SLITRK2 and SLITRK4 in brains from
DM1 patients support the hypothesis
that the effects of the DM1 mutation on
SLITRK members may contribute to the
behavioral phenotypes observed in DM1
patients. At the least, this study provides
a new target for investigating the
pathology of DM1 in the brain in the
many existing mouse models of RNA
toxicity and highlights the potential of
studies using hESCs to help unravel the
pathogenesis of DM1 and other rare
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Transplanted, c-kit expressing marrow-derived progenitors can enhance the function of an infarcted heart,
but the mechanism remains unclear. In this issue of Cell Stem Cell, Loffredo et al. (2011) provide evidence
that hematopoietic precursors do not differentiate into new cardiomyocytes but, rather, stimulate production
of new cardiomyocytes from endogenous progenitors.The stem cell biology field is no stranger
to paradigm shifts, in particular when
reevaluating presumed terminally differ-
entiated tissue. As has been the case in
several adult tissues, much interest over
the past decade has been directed to the
possibility that regenerative progenitor
cells exist in the mature heart. The
hearts of amphibians and teleost fish
retain the ability to regenerate throughout
life, and recent work in zebrafish has
demonstrated this repair process occurs
principally through division of pre-existingcardiomyocytes (Kikuchi et al., 2010).
Interestingly, the mouse heart retains the
ability to regenerate for a few days after
birth, again through cardiomyocyte divi-
sion, but this replication competence is
lost within the first week of postnatal life
(Porrello et al., 2011). While mature
mammalian hearts clearly lack a robust
regenerative response, mounting evi-
dence points to some capacity for cardio-
myocyte renewal. In 2007, Richard Lee’s
group performed a lineage tracing experi-
ment to elegantly demonstrate that,indeed, the young adult mouse heart can
generate new cardiomyocytes post
myocardial infarction (Hsieh et al., 2007).
Using this system, they fluorescently
labeled 80% of the pre-existing cardio-
myocytes and then demonstrated that,
8 weeks post-myocardial infarction, the
percentage of fluorescently labeled
mature cardiomyocytes had fallen to
roughly 65%, with 15% new cardiomyo-
cytes likely arising from a progenitor pop-
ulation. Since this study, Frisen’s group
demonstrated that the adult human heart
